These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27190596)

  • 1. Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.
    Hatcher JM; Weisberg E; Sim T; Stone RM; Liu S; Griffin JD; Gray NS
    ACS Med Chem Lett; 2016 May; 7(5):476-81. PubMed ID: 27190596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.
    Katayama K; Noguchi K; Sugimoto Y
    Oncotarget; 2018 Sep; 9(76):34240-34258. PubMed ID: 30344940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
    Weisberg EL; Puissant A; Stone R; Sattler M; Buhrlage SJ; Yang J; Manley PW; Meng C; Buonopane M; Daley JF; Lazo S; Wright R; Weinstock DM; Christie AL; Stegmaier K; Griffin JD
    Oncotarget; 2017 Aug; 8(32):52026-52044. PubMed ID: 28881711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
    Aikawa T; Togashi N; Iwanaga K; Okada H; Nishiya Y; Inoue S; Levis MJ; Isoyama T
    Oncotarget; 2020 Mar; 11(11):943-955. PubMed ID: 32215183
    [No Abstract]   [Full Text] [Related]  

  • 5. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
    Wang ES
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
    Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
    Heng H; Zhi Y; Yuan H; Wang Z; Li H; Wang S; Tian J; Liu H; Chen Y; Lu T; Ran T; Lu S
    Eur J Med Chem; 2019 Feb; 163():195-206. PubMed ID: 30508668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
    Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
    Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
    Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
    Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quizartinib (AC220): a promising option for acute myeloid leukemia.
    Zhou F; Ge Z; Chen B
    Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia.
    Czardybon W; Windak R; Gołas A; Gałęzowski M; Sabiniarz A; Dolata I; Salwińska M; Guzik P; Zawadzka M; Gabor-Worwa E; Winnik B; Żurawska M; Kolasińska E; Wincza E; Bugaj M; Danielewicz M; Majewska E; Mazan M; Dubin G; Noyszewska-Kania M; Jabłońska E; Szydłowski M; Sewastianik T; Puła B; Szumera-Ciećkiewicz A; Prochorec-Sobieszek M; Mądro E; Lech-Marańda E; Warzocha K; Tamburini J; Juszczyński P; Brzózka K
    Oncotarget; 2018 Mar; 9(24):16917-16931. PubMed ID: 29682194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date.
    Fletcher L; Joshi SK; Traer E
    Cancer Manag Res; 2020; 12():151-163. PubMed ID: 32021432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.
    Weisberg E; Roesel J; Furet P; Bold G; Imbach P; Flörsheimer A; Caravatti G; Jiang J; Manley P; Ray A; Griffin JD
    Genes Cancer; 2010 Oct; 1(10):1021-32. PubMed ID: 21779428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in
    Garz AK; Wolf S; Grath S; Gaidzik V; Habringer S; Vick B; Rudelius M; Ziegenhain C; Herold S; Weickert MT; Smets M; Peschel C; Oostendorp RAJ; Bultmann S; Jeremias I; Thiede C; Döhner K; Keller U; Götze KS
    Oncotarget; 2017 Dec; 8(65):108738-108759. PubMed ID: 29312564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE
    PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
    Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.
    Weisberg E; Sattler M; Manley PW; Griffin JD
    Onco Targets Ther; 2018; 11():175-182. PubMed ID: 29343975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.